Equine papillomavirus type 1: complete nucleotide sequence and characterization of recombinant virus-like particles composed of the EcPV-1 L1 major capsid protein.

The research article discusses the detailed examination and sequencing of Equus caballus papillomavirus type 1 (EcPV-1), a type of equine papillomavirus. The study also evaluates the potential of virus-like particles (VLPs) composed of EcPV-1’s major capsid protein to act as a noninfectious vaccine candidate for equine cutaneous papillomatosis.

Sequencing and Analysis of EcPV-1

• The isolation of EcPV-1 was carried out from a horse’s cutaneous papilloma, which is a common type of tumor observed in horses.
• Through analyzing the complete nucleotide sequence and genomic structure of the virus, the researchers were able to establish its phylogenetic position. In evolution terms, EcPV-1 is a fundamental papillomavirus type having distant relationships to fibropapillomaviruses and benign cutaneous papillomaviruses.

Production of EcPV-1 Virus-Like Particles (VLPs)

• For the production of VLPs, the researchers employed a technique involving the expression of EcPV-1’s L1 major capsid protein in insect cells via a baculovirus vector. This vector encourages the cells to produce the protein.
• The resultant VLPs were structurally identical to wild type papillomavirus virions, demonstrating their capacity to self-assemble into functional virus-like structures in vitro.

Monoclonal Antibodies and VLPs

• Monoclonal antibodies, produced specifically against these EcPV-1 VLPs, were also studied. These antibodies were developed against both intact and denatured VLPs.
• ELISA testing confirmed that these antibodies were successful in identifying intact EcPV-1 VLPs, suggesting they contains type-specific conformational and linear epitopes or specific binding sites on their surface, crucial for immune response.

Potential for Vaccine Development

• Given that the produced VLPs were equivalent to the wild type virus, and that the developed antibodies were successful in identifying these, the study concludes with the potential of these VLPs to be used as noninfectious vaccines.
• If further validated and developed, such a vaccine could effectively prevent or eradicate equine cutaneous papillomatosis in horses, having a significant impact on equine health.